Enhancing shareholder value through exceptional business performance and practices, and through responsible and effective communication with its shareholders.
HT-ALZ is under investigation for treatment and/or prevention of Alzheimer’s disease and other neuroinflammatory diseases.
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that is associated with the destruction of higher brain structures, such as those involved in memory and cognition. The disease leads to deficits in cognitive function and declines in memory, learning, language, and in the ability to perform intentional and purposeful movements. The disease is predicted to increase at least threefold between 2000 and 2050, rendering AD a world-wide public health problem.
HT-ALZ is being developed for pursuit of the 505(b)(2) regulatory pathway, relying on information that Hoth does not have right of reference.
HT-ALZ is in the early preclinical stage of development.
Hoth intends to initiate proof of concept animal model studies in Q3 2021.